Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 1, 2041

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG

CD19-CAR_Lenti_ALLO

"Biological/Vaccine: CD19-CAR\_Lenti\_ALLO~A single infusion of CD19-CAR\_Lenti\_ALLO on Day 0"

Trial Locations (1)

RECRUITING

Ospedale Pediatrico Bambino Gesù, Rome

All Listed Sponsors

lead

Bambino Gesù Hospital and Research Institute

OTHER